Top Insider Trades: GEVA, ACW, BIND, WFT

By Jonathan Moreland, founder of Insider Insights and author of Profit From Legal Insider Trading.

NEW YORK ( TheStreet) -- It is a victory for common sense. Tracking the trading behavior of company executives, directors and large shareholders in the stocks of firms they're registered in as "insiders" has proven to be profitable, according to both academic studies and (more importantly) the experience of professional investors.

Below are lists of the top 10 mainly open-market insider purchases and sales filed at the Securities and Exchange Commission Friday, Sept. 27, 2013 as ranked by dollar value. Please note, however, that these are only factual lists, not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

So use these regular Top Insider Trades columns as the initial research tools they are meant to be, and click the links in the tables to analyze a company's or insider's full insider history. Also feel free to contact us with any questions on our proprietary insider data, and how it is best analyzed.
Synageva (GEVA) Baker J DIR,BO 1,050,000 59,461,500
Accuride (ACW) Coliseum BO 414,481 2,139,591
Bind Thera (BIND) Rusnano BO 120,000 1,800,000
Weatherford (WFT) Macaulay W DIR 78,000 1,189,890
Aircastle (AYR) Marubeni DIR,BO 30,000 523,983
Premier (PINC) Devore S PR,CEO,DIR 15,000 405,000
Bind Thera (BIND) Polaris BO 26,000 390,000
Bind Thera (BIND) Flagship BO 20,000 300,000
Premier (PINC) Lemkin J GC 10,000 270,000
Premier (PINC) Alkire M COO 10,000 270,000
Source: Insider Insights
Google (GOOG) Schmidt E CB,DIR 101,949 89,547,998
Regional (RM) Palladium DIR,BO 2,547,335 66,899,384
Regional (RM) Parallel 2005 DIR,BO 1,454,665 38,203,140
Finisar (FNSR) Rawls J CB,DIR 706,172 16,139,879
Ruckus (RKUS) Lo S Y PR,CEO,DIR 306,600 5,117,928
ITT Educ (ESI) Blum BO 164,532 5,102,359
Sonic (SONC) Richardson F DIR 150,000 2,700,342
FXCM (FXCM) Wilhelm M BO 124,826 2,411,359
Sapient (SAPE) Moore J S DIR 100,000 1,571,000
Tibco (TIBX) Rode M D VP,COO 60,000 1,550,478
Source: Insider Insights

Key to Titles: A=Assistant, AI=Affiliated Investor, AO=Accounting Officer, BD=Business Development, BO=Beneficial Owner, CAO=Chief Accounting Officer, CB=Chairman, CCO=Chief Compliance Officer, CEO=Chief Executive Officer, CFO=Chief Financial Officer, CIO=Chief Information Officer, CO=Compliance Officer, COO=Chief Operating Officer, CT=Controller, CTO=Chief Technology Officer, DIR=Director, EVP=Executive Vice President, F=Founder, FO=Financial Officer, GC=General Counsel, HR=Human Resources, IO=Information Officer, IR=Investor Relations, LO=Legal Officer, MD=Managing Director, O=Officer, OO=Operating Officer, PR=President, PT=Partner, REL=Relative of an insider, SEC=Secretary, SH=Shareholder, SO=Sales Officer, TO=Technology Officer, TR=Treasurer, TT=Trustee, VCB=Vice Chairman, VP=Vice President, X=Ex Officer or other title displayed.
Jonathan Moreland is the founder of InsiderInsights.com, which produces a weekly newsletter and offers professional screening and alerting tools to analyze a proprietary, real-time insider data feed. He is also the principal of Insider Asset Management, a registered investment advisor in New York. Mr. Moreland has been analyzing insider data professionally for two decades and has been a contributor to TheStreet.com since 2001. A fundamental analyst with an MBA in finance, Mr. Moreland long ago identified insider data as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis and stock recommendations stemming from it. He is also author of Profit From Legal Insider Trading.

Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. While he cannot provide investment advice or recommendations, Moreland appreciates your feedback; click here to send him an email.

If you liked this article you might like

The Nominees for Best Biopharma CEO of 2015 Are...

Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

New Lifetime High Today: Synageva BioPharma (GEVA)

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years